Compounds > trihexyphenidyl
Page last updated: 2024-11-05

trihexyphenidyl and Amyotonia Congenita

trihexyphenidyl has been researched along with Amyotonia Congenita in 2 studies

Trihexyphenidyl: One of the centrally acting MUSCARINIC ANTAGONISTS used for treatment of PARKINSONIAN DISORDERS and drug-induced extrapyramidal movement disorders and as an antispasmodic.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Tanaka, K1
Wada, I1
Okunomiya, T1
Shima, A1
Kambe, D1
Shinde, A1
Kageyama, T1
Suenaga, T1
Hattori, N1

Reviews

1 review available for trihexyphenidyl and Amyotonia Congenita

ArticleYear
[Neuromuscular disorders due to adverse effects of antiparkinson agents].
    Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2007, Aug-10, Volume: 96, Issue:8

    Topics: Amantadine; Antiparkinson Agents; Catechols; Dopamine Agonists; Humans; Levodopa; Monoamine Oxidase

2007

Other Studies

1 other study available for trihexyphenidyl and Amyotonia Congenita

ArticleYear
Dropped head syndrome preceding the onset of dementia with Lewy bodies.
    Internal medicine (Tokyo, Japan), 2014, Volume: 53, Issue:8

    Topics: Aged; Brain; Cholinergic Antagonists; Female; Humans; Iofetamine; Lewy Body Disease; Magnetic Resona

2014